Antidepressants and Methylation — Why Biochemistry May Matter More Than Diagnosis Alone

Why "let's try another medication" often fails in treatment-resistant depression

The standard approach when an antidepressant isn't working is to switch molecules within the same class (one SSRI for another), or to add an augmenting agent (lithium, an atypical antipsychotic). This approach assumes depression is a single disorder with one underlying mechanism that only varies in intensity.

Walsh's research challenges this assumption. His database shows that depression has at least five distinct biochemical patterns, and each one responds to a different class of medication. For one pattern, an SSRI works beautifully; for another, it essentially can't work at all, because synaptic serotonin is already high and the problem lies elsewhere.

Without knowing the biochemical pattern, choosing a medication is essentially a roll of the dice. The statistics confirm it: the STAR*D study (one of the largest psychiatric trials ever conducted, ~4,000 patients) found that remission after a first SSRI occurs in only ~37% of patients, and after the fourth treatment step only ~13% remain in remission. Trial-and-error in depression treatment is costly — financially, in time, and for the patient themselves.

Methylation in one sentence: what it is and why it drives SSRI response

Methylation is a biochemical process in which the body "attaches" a small methyl group (-CH3) to another molecule. It happens billions of times per second — switching genes on and off, breaking down neurotransmitters, detoxifying the liver, and regulating immunity.

For psychiatry, one fact matters most: methylation directly controls the activity of the serotonin transporter (SERT) and dopamine transporter (DAT). SERT and DAT are "vacuums" that pull serotonin and dopamine out of the synaptic gap. SSRIs work by blocking these vacuums — serotonin stays in the synapse longer and the signal is stronger.

Walsh's data show that in undermethylation, SERT/DAT activity is elevated (the vacuums run at full speed, synaptic serotonin is low). In overmethylation, the opposite occurs — the vacuums work weakly and synaptic serotonin is already high. Adding an SSRI to this state pours fuel on the fire.

Undermethylation (~60–70% of methylation-affected cases)

Biochemical picture: low SAM activity, high blood histamine (>70 ng/ml), elevated SERT/DAT activity, low functional synaptic serotonin.

Typical client: depression since youth, perfectionism, obsessive thinking, competitiveness, seasonal allergies, strong inner discipline, higher libido.

The choice and suitability of any specific medication is decided solely by the treating physician.

A trap worth noting: many clients with undermethylation describe an initial good response to an SSRI that fades after 6–12 months — they experience "emotional flattening" and anhedonia. At that point, targeted methylation support (SAMe, methionine, calcium) is often needed, not simply a higher dose of the medication.

Overmethylation (~30–40% of methylation-affected cases)

Biochemical picture: high SAM activity, low blood histamine (<40 ng/ml), reduced SERT/DAT activity, paradoxically high synaptic serotonin and dopamine levels associated with anxiety, panic, and paranoid features.

Typical client: high anxiety, panic, chemical sensitivity, often no seasonal allergies, dry eyes and mouth, higher pain threshold. SSRIs can make this client worse — adding an SERT blocker on top of already-high synaptic neurotransmitter levels produces exactly the opposite of what the client needs.

The choice and suitability of any specific medication is decided solely by the treating physician.

Who this distinction is critical for: people who developed panic, akathisia, suicidal thoughts, or a paradoxical worsening after starting an SSRI. Some of them likely belong to the overmethylation biotype — for them, the correct nutritional strategy is the opposite: folate, B12, niacin, which reduce excessive methylation.

Why an MTHFR test alone isn't enough

The MTHFR test has become popular over the past decade — clients often get it hoping it will explain their treatment-resistant depression. Walsh's view is more sober: MTHFR genotype only shows potential, not actual function. A person with the C677T mutation may methylate completely normally. Conversely, a client without the mutation can have severe undermethylation caused by stress, oxidative burden, or cofactor deficiency.

Functional tests are more practical:

• Total whole-blood histamine — an indirect but clinically validated marker of methylation status (>70 ng/ml = undermethylation, <40 ng/ml = overmethylation)
• Plasma methylation panel (SAM, SAH, SAM/SAH ratio) — a direct indicator of current methylation capacity
• Homocysteine — a contextual marker, not sufficient on its own
• Copper, zinc, ceruloplasmin — cofactors whose imbalance can mimic or worsen the methylation picture

This is covered in detail in a separate article, Whole-Blood Histamine vs. Plasma Methylation Testing.

High copper: when even the right SSRI can't work properly

Copper overload causes destabilization of the catecholamine system. Free (unbound) copper affects noradrenaline release from vesicles and, through oxidative stress, degrades dopamine before it is even released into the synapse. The result: high noradrenaline + low functional dopamine — a combination that shows up as anxiety with exhaustion, restlessness, and agitation without energy.

In this state, an SSRI alone cannot correct the picture, even if methylation is otherwise fine — the problem isn't in the serotonin pathway but in the dopamine-noradrenaline one. A targeted intervention: zinc supplementation (a copper antagonist), B6, vitamin C, and ceruloplasmin support. Details in the article High Copper — Symptoms and Mechanisms.

Practical implication: if postpartum depression (95% of cases show elevated copper) were addressed by treating copper overload first and only then considering an antidepressant, some clients might not need medication at all.

When switching or gradually discontinuing a medication makes sense

If a client's biotype does not match the molecule they have been taking long-term, a gradual switch or discontinuation, done in collaboration with a psychiatrist, can restore what the "wrong" antidepressant had been suppressing for years — emotional depth, motivation, libido, and a fuller sense of experience.

Targeted nutritional support that compensates for the medication's effect from within can help during discontinuation. Specifically, for undermethylation, methyl donors are used — SAMe, methionine, vitamin B12, and TMG (trimethylglycine, betaine). These increase methyl group availability, support transporter activity, and help the brain transition to a state where the medication is less needed. For overmethylation, the opposite approach applies — folate, B12, niacin.

PsyLab is not a psychiatric clinic. We facilitate testing, evaluation, and consultation — the actual change in medication is made by your psychiatrist or general practitioner. For a detailed approach to discontinuation (hyperbolic tapering, decrement schedules, timeframes), see the separate article How to Gradually Discontinue Antidepressants.

The logic of the orthomolecular approach is: test first, then provide targeted nutritional support for the specific biotype, and only once biochemistry is stabilized, consider adjusting treatment in collaboration with the treating psychiatrist.

A practical first step

If cycling through medications is wearing you down and you want to know whether an outside perspective could help, the most effective entry point is:

1. Complete the free 5-minute screening — it will indicate which biotype you likely fall into.

2. If your symptoms match, order the Whole-Blood Histamine Test (€149) — it distinguishes undermethylation from overmethylation.

3. If high copper is suspected, add the copper / ceruloplasmin / zinc panel.

4. After the results, book a 45-minute consultation (€75) — we'll review the results and suggest what may be worth discussing with your psychiatrist.